MYGN May 2022 28.000 call
| Previous Close | 1.6000 |
| Open | 1.6000 |
| Bid | 2.2000 |
| Ask | 3.6000 |
| Strike | 28.00 |
| Expire Date | 2022-05-20 |
| Day's Range | 1.6000 - 1.6000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 7 |
- Zacks
Myriad Genetics (MYGN) Reports Loss in Q1, Gross Margin Down
Myriad Genetics' (MYGN) sales in the majority of the operating segments improved in the first quarter despite a challenging business environment.
- Zacks
Myriad Genetics (MYGN) Reports Q1 Loss, Tops Revenue Estimates
Myriad (MYGN) delivered earnings and revenue surprises of 40% and 3.98%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Myriad Genetics Reports First Quarter Revenue and Reiterates Guidance for 2022
Highlights: Revenue of $164.9 million for the quarter ended March 31, 2022 Excluding revenue from divested businesses, revenue increased 11% year-over-year Diluted GAAP earnings per share (EPS) of $(0.26) and adjusted EPS of $(0.03) in the first quarter of 2022 improved by $0.26 and $0.03 year-over-year, respectivelyEnded the quarter with $339.2 million in cash, cash equivalents and investmentsNew partnership with Intermountain Precision Genomics to launch Precise™ Liquid Biopsy Therapy Selectio
